OncoMatch/Clinical Trials/NCT06851663
Trop2-targeted immunoPET Imaging of Solid Tumors
Is NCT06851663 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments including [68Ga]Ga-NOTA-T4 and [68Ga]Ga-NOTA-RT4 for solid tumor.
Treatment: [68Ga]Ga-NOTA-T4 · [68Ga]Ga-NOTA-RT4 · [18F]F-RESCA-T4 · [18F]F-RESCA-RT4 — This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and its physiological and pathological distribution characteristics, based on which the diagnostic efficacy of the above imaging agents in solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) will be evaluated.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Urothelial Carcinoma
Prostate Cancer
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma
Hepatocellular Carcinoma
Cholangiocarcinoma
Ovarian Cancer
Cervical Cancer
Endometrial Cancer
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06851663 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages